The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

被引：0
|
作者：
Karl-Anton Kreuzer
Richard R. Furman
Stephan Stilgenbauer
Ronald L. Dubowy
Yeonhee Kim
Veerendra Munugalavadla
Esther Lilienweiss
Hans Christian Reinhardt
Paula Cramer
Barbara Eichhorst
Peter Hillmen
Susan M. O’Brien
Andrew R. Pettitt
Michael Hallek
机构：
[1] University of Cologne,Department I of Internal Medicine
[2] Weill Cornell Medical College,Department III of Internal Medicine
[3] Ulm University Medical Center,Center for Molecular Medicine Cologne, and Cologne Excellence Cluster on Cellular Stress Responses in Aging
[4] Gilead Sciences,Associated Diseases (CECAD)
[5] Inc.,undefined
[6] University of Cologne,undefined
[7] St. James’s University Hospital,undefined
[8] University of California-Irvine,undefined
[9] Irvine Chao Family Comprehensive Cancer Center,undefined
[10] University of Liverpool,undefined
来源：
Leukemia | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 300
页数：4
相关论文
共 50 条
  • [1] The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
    Kreuzer, Karl-Anton
    Furman, Richard R.
    Stilgenbauer, Stephan
    Dubowy, Ronald L.
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweiss, Esther
    Reinhardt, Hans Christian
    Cramer, Paula
    Eichhorst, Barbara
    Hillmen, Peter
    O'Brien, Susan M.
    Pettitt, Andrew R.
    Hallek, Michael
    LEUKEMIA, 2020, 34 (01) : 296 - 300
  • [2] Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab
    Kreuzer, Karl-Anton
    Furman, Richard
    Stilgenbauer, Stephan
    Dubowy, Ronald
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweisz, Esther
    Reinhardt, Hans Christian
    Cramer, Paula
    Eichhorst, Barbara
    Hillmen, Peter
    O'Brien, Susan
    Pettitt, Andrew
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 167 - 168
  • [3] Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
    Kreuzer, Karl-Anton
    Furman, Richard R.
    Stilgenbauer, Stephan
    Dubowy, Ronald L.
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweiss, Esther
    Reinhardt, Hans Christian
    Pettitt, Andrew R.
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [4] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
    Furman, Richard R.
    Sharman, Jeff P.
    Coutre, Steven E.
    Cheson, Bruce D.
    Pagel, John M.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian
    Ghia, Paolo
    Eradat, Herbert
    Ervin, Thomas
    Lamanna, Nicole
    Coiffier, Bertrand
    Pettitt, Andrew R.
    Ma, Shuo
    Stilgenbauer, Stephan
    Cramer, Paula
    Aiello, Maria
    Johnson, Dave M.
    Miller, Langdon L.
    Li, Daniel
    Jahn, Thomas M.
    Dansey, Roger D.
    Hallek, Michael
    O'Brien, Susan M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11): : 997 - 1007
  • [5] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    HEMASPHERE, 2018, 2 (03):
  • [6] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [7] IDELALISIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A COST-EFFECTIVENESS ANA LYSIS
    Yu, J. S.
    Seal, B.
    Carlson, J. J.
    VALUE IN HEALTH, 2015, 18 (03) : A203 - A203
  • [8] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [9] Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Chaffee, Kari G.
    Furman, Richard R.
    Hillmen, Peter
    Sharman, Jeff
    Seymour, John F.
    Chanan-Khan, Asher A.
    Byrd, John C.
    Jones, Jeffrey A.
    Ferrante, Lucille A.
    Dreiling, Lyndah K.
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Howes, Angela J.
    James, Danelle
    Bhargava, Pankaj
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [10] Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases
    Morabito, Fortunato
    Tripepi, Giovanni
    Del Poeta, Giovanni
    Mauro, Francesca Romana
    Reda, Gianluigi
    Sportoletti, Paolo
    Laurenti, Luca
    Coscia, Marta
    Herishanu, Yair
    Bossio, Sabrina
    Varettoni, Marzia
    Murru, Roberta
    Chiarenza, Annalisa
    Visentin, Andrea
    Condoluci, Adalgisa
    Moia, Riccardo
    Pietrasanta, Daniela
    Loseto, Giacomo
    Consoli, Ugo
    Scortechini, Ilaria
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Al-Janazreh, Hamdi
    Vigna, Ernesto
    Martino, Enrica Antonia
    Mendicino, Francesco
    Cassin, Ramona
    D'Arrigo, Graziella
    Galimberti, Sara
    Rago, Angela
    Angeletti, Ilaria
    Biagi, Annalisa
    Del Giudice, Ilaria
    Bomben, Riccardo
    Neri, Antonino
    Fronza, Gilberto
    Monti, Paola
    Menichini, Paola
    Cutrona, Giovanna
    Jaksic, Ozren
    Rossi, Davide
    Di Raimondo, Francesco
    Cuneo, Antonio
    Gaidano, Gianluca
    Polliack, Aaron
    Trentin, Livio
    Foa, Robin
    Ferrarini, Manlio
    Gattei, Valter
    Gentile, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 493 - 499
12345